PRINCETON, N.J., Aug. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30,… Read More..

Conference Call to be held Thursday, August 13, 2020 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June… Read More..

- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track, with multiple data readouts expected in next 18 months - NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.… Read More..